Facilitating expedited assessment of pulmonary embolism severity, the emerging artificial intelligence (AI) tool Rapid RV/LV reportedly calculates the right ventricle/left ventricle (RV/LV) ratio within minutes of a computed tomography pulmonary angiogram (CTPA).
The Food and Drug Administration (FDA) has granted 510(k) clearance for RapidAI’s Rapid RV/LV, an artificial intelligence (AI)-powered modality that provides expedited calculation of the right ventricle/left ventricle (RV/LV) ratio, a key factor for determining pulmonary embolism (PE) severity.
Integrated with the company’s previously FDA-cleared Rapid PE platform, Rapid RV/LV identifies potential right heart strain with automated measurement of RV/LV ratios within minutes of analyzing a computed tomography pulmonary angiogram (CTPA), according to RapidAI.
Peter Monteleone, M.D., FACC, FSCAI, said Rapid RV/LV will be a significant advance in the evaluation of elevated risk for pulmonary embolism, a disease that is commonly underdiagnosed.
“The ability to access the RV/LV ratio along with CTPA images will allow clinicians to quicky identify patients who would benefit from further treatment, improving patient outcomes and saving lives,” emphasized Dr. Monteleone, an interventional cardiologist at Ascension Texas Cardiovascular in Austin, Tx., and assistant professor in the Department of Internal Medicine at Dell Medical School at the University of Texas at Austin. “This will have a profound impact on our PE program here at Ascension.”
(Editor’s note: For related content, see “Can Deep Learning Assessment of X-Rays Improve Triage of Patients with Acute Chest Pain?” and “Viz.ai Gets FDA Clearance for New RV/LV Ratio Algorithm.”)
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
July 22nd 2025In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.